ArticleBioImpacts : BI2025
Exploring the potential of tubulin-associated unit protein as a biomarker for schizophrenia.
Article in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Schizophrenia is a chronic and debilitating psychiatric disease characterized by various causes and symptoms. The tau protein is recognized as a biomarker that plays a crucial role in neurocognitive and neurodegenerative diseases. Given the presence of cognitive symptoms in individuals with schizophrenia, the objective of this study was to measure to evaluate the diagnostic potential of measuring serum levels of total tau and phosphorylated tau in patients with schizophrenia. Methods: A total of 40 patients with schizophrenia who met the inclusion criteria were selected, along with 40 age- and sex-matched healthy individuals. Written consent was obtained from all participants, and blood samples were collected to measure the serum levels of total tau protein and phosphorylated tau. The obtained data were analyzed using appropriate statistical methods with SPSS 23 software. Results: There was no statistically significant disparity detected in the serum concentrations of total and phosphorylated tau protein when comparing individuals with schizophrenia to those without the disorder. Conclusion: Based on the results obtained, it can be concluded that total tau protein and phosphorylated tau cannot be considered as diagnostic biomarkers for schizophrenia. Furthermore, the findings of this study do not support the presence of neuroanalysis in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.